Travere Therapeutics, Inc. — FY2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023. The filing is an annual report, not a standalone Q4 filing; quarterly figures below are unaudited. Travere is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead commercial product, FILSPARI (sparsentan), received U.S. accelerated approval in February 2023 for reducing proteinuria in certain adults with primary IgAN.
Financial performance and liquidity
| Metric | FY2023 | FY2022 |
|---|---|---|
| Total revenue | $145.2 million | $109.5 million |
| Net product sales | $127.5 million | $98.0 million |
| Operating loss | $388.1 million | $319.8 million |
| Loss from continuing operations, net | $376.3 million | $331.5 million |
| Income from discontinued operations, net | $264.9 million | $53.0 million |
| Net loss | $111.4 million | $278.5 million |
| Cash used in operating activities | $280.0 million | $186.3 million |
| Cash and marketable debt securities | $566.9 million | $450.2 million |
- 2023 product sales included $29.2 million from FILSPARI and $98.3 million from tiopronin products. License and collaboration revenue was $17.7 million.
- Operating expenses rose to $533.4 million, including $245.0 million of R&D, $265.5 million of SG&A, and $11.4 million of restructuring charges. The filing does not report a single consolidated gross-margin metric.
- FY2023 net loss included a $226.0 million after-tax gain on the bile acid portfolio sale. Continuing operations remained loss-making; reported net loss therefore does not reflect the underlying continuing-operations loss.
- At year-end, cash and cash equivalents were $58.2 million and available-for-sale marketable debt securities were $508.7 million. Net working capital was $438.9 million; the reported current ratio was 3.47.
- Convertible debt had a $377.3 million carrying value; principal outstanding was approximately $385.2 million: $68.9 million of 2.50% notes due 2025 and $316.3 million of 2.25% notes due 2029.
Quarterly context and changes
In Q4 2023, revenue was $45.1 million, operating loss was $94.2 million, loss from continuing operations was $88.6 million, and net loss was $90.2 million. The Q3 net income reflected the bile acid sale gain; Q4 did not.
- Annual revenue increased 32.7%, mainly from the FILSPARI launch; tiopronin sales were nearly flat year over year. Comparatively, 2022 tiopronin revenue had declined from 2021 amid generic competition.
- Operating loss widened by $68.3 million as R&D and SG&A increased, including commercial launch costs and investment in pegtibatinase development. Operating cash use increased by $93.7 million.
- Travere sold substantially all assets of its bile acid business to Mirum for $210.0 million upfront and may receive up to $235.0 million in sales-based milestones. The business is reported as discontinued operations.
- The company raised approximately $215.8 million net through a February 2023 public offering of common stock and pre-funded warrants.
Outlook, developments, and principal risks
- Management expects available cash and short-term investments, together with anticipated operating cash generation, to fund planned operations beyond the next 12 months. It expects approximately $50 million in net milestone payments over the next 12 months. This is management’s expectation, not a guarantee; further financing may be needed depending on results, spending, and debt requirements.
- A December 2023 reorganization reduced the workforce by approximately 20%, primarily non-field staff. Management estimates annualized savings of about $25 million beginning in 2024, with total one-time charges of $12–14 million; $11.4 million was recorded in 2023.
- For FILSPARI in IgAN, the confirmatory PROTECT study showed clinically meaningful eGFR results but narrowly missed statistical significance on the U.S. confirmatory eGFR total-slope endpoint; chronic-slope results were statistically significant for EU review. Travere planned to submit an sNDA for U.S. full approval in Q1 2024. Approval, label expansion, and continuation of accelerated approval remain uncertain.
- The Phase 3 DUPLEX study in FSGS did not meet its two-year primary eGFR endpoint with statistical significance. FDA indicated the results alone were insufficient to support an sNDA; Travere is conducting further analyses and pursuing regulatory discussions.
- The pivotal Phase 3 HARMONY study of pegtibatinase for classical homocystinuria began in December 2023; topline results are expected in 2026. The candidate’s earlier biomarker results do not establish Phase 3 success.
- Key risks include commercial uptake and reimbursement for FILSPARI; competing IgAN therapies; generic competition affecting Thiola and Thiola EC (including an FDA-approved generic Thiola EC version in January 2024); clinical and regulatory uncertainty; dependence on third-party manufacturers and distributors; and substantial R&D spending and debt obligations.
- Subsequent to year-end, Travere announced an exclusive Asian licensing agreement for sparsentan with Renalys, including an upfront payment and potential milestones of up to $120 million plus royalties. The filing does not state the upfront payment amount.
- The 2022 material weakness in controls over accounting for a pre-launch inventory contract was reported remediated as of December 31, 2023. Management and the auditor reported effective internal control over financial reporting; the financial statement audit opinion was unqualified.
Most important facts for investors to verify
- FILSPARI’s sales trajectory, net pricing and payer access, and the FDA’s decision on full approval and any label changes.
- Cash burn from continuing operations, milestone and royalty obligations, and the timing and funding plan for the 2025 notes.
- Whether further evidence or regulatory engagement creates a viable FSGS pathway after DUPLEX missed its primary endpoint.
- HARMONY enrollment, execution, safety, and results timing, including manufacturing and supply readiness.
- The impact of generics on Thiola and Thiola EC sales, and whether Mirum’s sales-based milestones are achieved.
- Whether the expected $25 million restructuring savings materialize without impairing launch and development execution.